| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
9 |
/ |
2021 |
|
|
|
| |
Data sporządzenia: |
2021-03-10 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Receiving a Notice of Allowance for European Patent Related to Combination of Nerve
Stimulation and DPS Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location
in Ultrasound-Guided PNB Procedures
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_,
today announced that Milestone Scientific, Inc. _NYSE:MLSS_, the licensor and the
majority shareholder of the Issuer has received Notice of Allowance from the European
Patent Office _EPO_ combining minimum intensity of nerve stimulation _MIS_ and real-time
injection pressure _IP_ monitoring utilizing Milestone’s CompuFlo® instrument and
associated DPS Dynamic Pressure Sensing Technology® to optimize needle tip location
in ultrasound-guided peripheral nerve block _PNB_ procedures.The technology was developed
in conjunction with Dr. Olivier Choquet from the Lapeyronie University Hospital Montpellier
France, a renowned expert in peripheral nerve block procedures, and Dr. Mark Hochman,
D.D.S., Inventor and Clinical Director for Milestone Scientific.
The Board of Directors of the Company commented that this is an important event, as
receiving this notice-of-allowance from the European Patent Office clears an important
hurdle as the Company seeks to develop a device specifically for PNB procedures, which
will incorporate the CompuFlo® with Dynamic Pressure Sensing Technology® capabilities
of precisely measuring, displaying, controlling, warning and recording needle tip
pressure in real time. The optimization of a device specifically for procedures that
also integrates this new technology, The Board of Directors of the Company believes
will help reduce the risk of needle injury during PNB procedures. By combining CompuFlo
with ultrasound guidance and MIS, The Board of Directors of the Company believes it
will achieve unparalleled multimodal PNB monitoring, safety and greater accuracy to
identify needle tip location during PNB procedures. The Board of Directors of the
Company is grateful for the contributions of Dr. Choquet and his team who helped understand
the value of this breakthrough technology. The Board of Directors of the Company
views this as an attractive market for our technology as PNBs are increasingly utilized
in the treatment of trauma and surgical procedures, including orthopedic surgeries
as well as for postoperative and nonsurgical analgesia. In addition to Europe, the
licensor has applied for similar patents in the United States and remains focused
on building our IP portfolio across numerous indications and around the world.
|
|
|
RB_ASO: Receiving a Notice of Allowance for European Patent Related to Combination of Nerve
Stimulation and DPS Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location
in Ultrasound-Guided PNB Procedures
